{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The distribution of duration of response will be estimated using the method of Kaplan-Meier.","groups":[{"description":"Participants were accrued at 50 mg/m\\^2 dose level after December 30, 2009 addendum. Participants to receive 50 mg/m\\^2 dinaciclib IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Phase II"}],"populationDescription":"Duration of Response was not analyzed due to lack of responses.","reportingStatus":"POSTED","timeFrame":"Date at which the patient's objective status is first noted to be either an sCR, CR, PR, or VGPR to the earliest date progression is documented, assessed up to 3 years","title":"Duration of Response","type":"SECONDARY"}